http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
The Practice of Medicinal Chemistry, Fourth Edition, provides a practical and comprehensive overview of the daily issues facing pharmaceutical researchers and chemists. In addition to its thorough and excellent treatment of basic medicinal chemistry principles, this updated edition has been thoroughly revised to provide new and expanded coverage of the latest technologies and approaches in drug discovery. With in-depth coverage of high content screening, scoring, docking, binding free energy calculations, polypharmacology, QSAR, chemical collections and databases, and much more, this book is the go-to reference for all academic and pharmaceutical researchers who need a complete understanding of medicinal chemistry and its application to drug discovery and development.
Front Cover; The Practice of Medicinal Chemistry; Copyright Page; Contents; List of Contributors; Foreword; Preface to the Fourth Edition; Preface to the Third Edition; Preface to the Second Edition; Preface to the First Edition; I. General Aspects of Medicinal Chemistry; 1 Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems; I. Definitions and Objectives; A Medicinal Chemistry and Related Disciplines and Terms; B Drugs and Drug Substances; C Stages of Drug Development; II. Drug Activity Phases; A The Pharmaceutical Phase.
B The Pharmacokinetic PhaseC The Pharmacodynamic Phase; D The Road to Successful Drug Development?; III. Drug Classification Systems; A Classification by Target and Mechanism of Action; 1 Targets; 2 Mechanisms of Action; B Other Classification Systems; References; 2 Evaluation of the Biological Activity of Compounds: Techniques and Mechanism of Action Studies; I. Introduction; II. Drug Discovery Approaches and Screening Cascades; A Target Based Screening; B Phenotypic Screening; III. In Vitro Assays; A Primary Assays; Glossary; 1 Binding assays; 2 Binding Studies: Principles and Analysis.
3 Enzyme Assays4 Types of Enzyme Inhibition and Their Analysis; A Reversible Inhibitors; B Irreversible Inhibitors; C Competitive Inhibitors; D Noncompetitive Inhibitors; E Uncompetitive Inhibitors; 5 Functional Assays; 6 Functional Studies and Their Analysis; A Agonist Concentration-Effect (E/[A]) Curves; B Full Agonists, Partial Agonists, and Inverse Agonists; C Optimizing Agonists; D Analysis of Antagonists; Competitive Antagonists; Irreversible, Noncompetitive, and Allosteric Antagonists; B Compound Interference in Primary Assays: Artifacts and False Positives; C Assay Biostatistics.
D Selectivity, Cytotoxicity, and Species Cross-over. 1 Selectivity; 2 Cytotoxicity; 3 Species Crossover; E Cellular and Tissue Functional Responses; IV. Ex Vivo Assays; V. In Vivo Assays; A Pharmacokinetic Models; B Efficacy Models; C Safety Testing; Acknowledgements; References; 3 Drug Targets, Target Identification, Validation, and Screening; I. Introduction; II. What is a Drug Target?; III. The Purpose of Target Identification; A Target-Based Screening; B Phenotypic Screening; C Fast Follower Strategy; IV. Target Options and Treatment Options; V. Target Deconvolution and Target Discovery.
VI. Methods for Target Identification and ValidationA Affinity Chromatography; B Genetic Methods; C Haploinsufficiency Profiling in Yeast; D Analysis of Resistant Mutants; E siRNA for Target Validation; F Yeast Three-Hybrid System; G DNA Microarrays; H Comparative Profiling; I Analysis of the Pathophysiology; J The Study of Existing Drugs; K Systems Biology; L In Silico Simulation of the Human Patient; VII. Target Validation; VIII. Conclusion; References; II. Lead Compound Discovery Strategies; 4 Strategies in the Search for New Lead Compounds or Original Working Hypotheses; I. Introduction.
edited by Camille Georges Wermuth, David Aldous, Pierre Raboisson, Didier Rognan.
Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty
Includes bibliographical references and index.